In a deal set to boost its urology offerings, Boston Scientific said it will acquire NxThera for about $406 million.
The New Jersey Superior Court’s appellate division refused to reinstate a hernia mesh product liability lawsuit against Becton Dickinson's C.R. Bard because expert witnesses couldn't prove the design of the product was defective or that significant negligence occurred.
In 2017 Netflix brought Bill Nye back to television, this time with a talk show for adults. In this guide, we highlight episodes from the first two seasons of Bill Nye Saves the World that medtech professionals should appreciate.
Endologix reported positive results from ENCORE, a pooled analysis of several prospective studies evaluating polymer endovascular aneurysm repair using the company's Ovation abdominal stent graft systems.
Colibri has treated the first two patients in a feasibility study and cites Edwards Lifesciences as its main competition in the TAVR market.
Amazon has reportedly hooked a former FDA officer for its new healthcare business, but we still don't know much about this secretive new venture.
We asked readers to weigh in on Theranos founder and CEO Elizabeth Holmes's recent SEC settlement over fraud charges. Here's what survey respondents had to say about it.
Johnson & Johnson continues its exodus from the diabetes market and has received a $2.1B offer from Platinum Equity to acquire LifeScan.
Corindus Vascular tops revenue expectations for the fourth quarter of 2017 and gears up for tele-stenting trial with Mayo Clinic.
These eight medtech startups are facing off to see which has what it takes to make it in the industry. Vote for your favorite!
The SEC charged Theranos, its founder and CEO Elizabeth Holmes, and its former president Ramesh "Sunny" Balwani with raising more than $700 million from investors through an elaborate, years-long fraud in which they exaggerated or made false statements about the company's technology, business, and financial performance.
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
Medtronic continued to strengthen its TAVR story with 5-year-data recently presented at ACC18. The company is battling it out with Edwards in the U.S. market, while Boston Scientific seeks to find footing after delaying commercialization of the Lotus Edge valve.
Laborie Medical Technologies is poised to get a leg up in the urology market by acquiring Cogentix Medical for about $239 million.
Strong results from the MOMENTUM 3 clinical trial could help Abbott take a significant part of the destination therapy portion of the LVAD market from Medtronic.